Paper
A FIRST-IN-HUMAN, DUAL-PRODUCT BASE EDITED CELL THERAPY FOR CD40L DEFICIENCY X-LINKED HYPER IGM(XHIGM) SYNDROME: PROCESS DEVELOPMENT AND MANUFACTGURING FOR AUTOLOGOUS CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS AND T CELLS
Cytotherapy · 2026 · H. Lei, J. Jin, M. Ma et al.
